In a patient with NSTEMI whose family declines invasive intervention, currently taking clopidogrel (Plavix) 75 mg daily and allergic to aspirin, should I give a ticagrelor (Brilinta) loading dose before starting the maintenance dose of 90 mg twice daily, or can I start ticagrelor without a loading dose after stopping clopidogrel?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, give the ticagrelor 180 mg loading dose before starting 90 mg twice daily maintenance, even though the patient is already on clopidogrel.

For NSTEMI patients managed conservatively (non-invasively), you should administer a 180 mg loading dose of ticagrelor followed by 90 mg twice daily maintenance starting 6-12 hours after the load, regardless of prior clopidogrel therapy. 1, 2

Rationale for Loading Dose

The 2025 ACC/AHA guidelines explicitly recommend a 180 mg loading dose of ticagrelor for all NSTEMI patients (Table 7), with no distinction made for those already on clopidogrel 1. The FDA label similarly specifies initiating treatment with a 180 mg loading dose for ACS 2. This approach ensures:

  • Rapid, predictable platelet inhibition within 2 hours, reaching optimal levels needed for acute thrombotic protection 3
  • Overcoming any residual clopidogrel effect, which is less potent and more variable than ticagrelor
  • Standardized dosing that was proven effective in the PLATO trial, which demonstrated ticagrelor's superiority over clopidogrel in reducing cardiovascular death, MI, and stroke 1

Addressing the Aspirin Allergy

This is a critical consideration. The patient cannot receive aspirin due to allergy, which creates a deviation from standard dual antiplatelet therapy. However:

  • Ticagrelor monotherapy is still indicated as a P2Y12 inhibitor is recommended for all ACS patients to reduce MACE 1
  • The guidelines state that a P2Y12 inhibitor should be administered "in addition to aspirin" when possible, but aspirin allergy is an absolute contraindication 1
  • Consider this patient for P2Y12 inhibitor monotherapy, which recent evidence suggests may be reasonable in select circumstances, though this is primarily studied post-PCI 1

Practical Implementation

Step-by-step approach:

  1. Stop clopidogrel immediately - do not give another dose
  2. Administer ticagrelor 180 mg loading dose as soon as possible
  3. Wait 6-12 hours, then start ticagrelor 90 mg twice daily
  4. Continue for at least 12 months unless bleeding complications arise 1
  5. Monitor for dyspnea (occurs in ~14-21% of patients) - usually mild and resolves, but can lead to discontinuation 2
  6. Watch for bradyarrhythmias - ticagrelor can cause ventricular pauses and AV block 2

Common Pitfalls to Avoid

  • Don't skip the loading dose thinking clopidogrel provides adequate coverage - research shows that switching from clopidogrel to ticagrelor without a load is feasible 4, but guidelines and FDA labeling mandate the load for ACS 1, 2
  • Don't wait for clopidogrel to "wash out" - switch immediately as ticagrelor's superior potency will override clopidogrel's effects
  • Don't attempt to substitute another antiplatelet for aspirin - the patient will be on ticagrelor monotherapy, which is acceptable given the aspirin allergy
  • Don't discontinue ticagrelor abruptly if dyspnea develops - evaluate other causes first, as stopping increases risk of subsequent cardiovascular events 2

Conservative Management Context

Since the family declined invasive intervention, this patient represents a medically managed NSTEMI. The 2025 guidelines give ticagrelor a Class I, Level B-R recommendation for NSTEMI patients regardless of invasive vs. conservative strategy 1. Ticagrelor has demonstrated benefit in both invasively and conservatively managed patients, making it appropriate here despite the non-invasive approach.

Related Questions

In a patient already taking clopidogrel 75 mg daily, should the antiplatelet therapy be switched to ticagrelor?
In a patient already taking aspirin (acetylsalicylic acid) and clopidogrel (Plavix) who now has a non‑ST‑segment elevation myocardial infarction (NSTEMI), should a loading dose of aspirin be given again, and should the clopidogrel loading dose be repeated?
Is ticagrelor (Brilinta) effective without a loading dose?
Can ticagrelor (Brilinta) be prescribed together with enoxaparin (Lovenox)?
Do blood thinners such as aspirin and clopidogrel lower blood pressure?
Could a person with facial, lip, and nasal telangiectasias that bleed rarely and a 2.9 cm inferior mesenteric venous varix (not an arteriovenous malformation) have hereditary hemorrhagic telangiectasia?
In a 69-year-old patient on paliperidone (Invega), escitalopram (Lexapro), trazodone, valproic acid (Depakote), and carbidopa/levodopa (Sinemet) with worsening tremors, should I taper the paliperidone and restart a benzodiazepine or switch to quetiapine (Seroquel)?
Is it safe to use topical lidocaine as needed for pain during vaginal intercourse?
What medication and dosing regimen should be used for a cancer patient on chemotherapy with a renal transplant and impaired renal function (GFR ~33 mL/min) experiencing delirium with hallucinations, including PRN dosing for agitation?
If a provider is fraudulently billing Medicare at all of its facilities, does the government offer any rewards to the whistleblower who reports them?
What are the optimal antihypertensive medications for a patient who has just experienced an ischemic stroke?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.